Arika Resources Limited (ASX:ARI) Reports Significant Step-Out Drilling Results
Arika Resources (ASX:ARI) extends mineralisation at Pennyweight Point with significant new drill intercepts at Yundamindra.
Tag: Earnings Reports
Orica Limited (ASX:ORI) Announces First Half Business Update
Orica (ASX:ORI) reports strong first half EBIT and outlines key financial updates, including impairment charges and restructuring costs.
Inventis Limited (ASX:IVT) Reports 1H25 Sales Results and Outlines Growth and Cost-Cutting Initiatives
Inventis Limited (ASX:IVT) reports a 38% decline in 1H25 sales revenue, highlights Technology division growth and outlines cost-cutting and investment plans.
Guzman y Gomez Limited (ASX:GYG) Responds to ASX Compliance Inquiry on Half-Year Earnings
Guzman y Gomez Limited (ASX:GYG) confirms its half-year earnings aligned with market expectations in response to ASX compliance inquiry.
Clean Seas Seafood (ASX:CSS) Announces 1H FY25 Results
Clean Seas Seafood (ASX:CSS) reports a 10.4% revenue decline in 1H FY25 and announces a potential merger with Yumbah Aquaculture.
Xamble Group Limited (ASX:XGL) Reports Year-End Financial Results
Xamble Group Limited (ASX:XGL) reports a 15% revenue decline and a 16% increase in net loss for the year ended 31 December 2024.
Generation Development Group Limited (ASX:GDG) Reports Half Year Financial Results
Generation Development Group Limited (ASX:GDG) reports a 155% increase in revenue and a 1,699% rise in net profit for the half-year ended 31 December 2024.
PainChek Limited (ASX:PCK) Releases Half Year Results
PainChek Limited (ASX:PCK) reports a 27% revenue increase in its half-year results, highlighting growth and expansion into the US market.
Vection Technologies (ASX:VR1) Accelerates Path to Profitability with Strong 1H25 Results
Vection Technologies (ASX:VR1) reports a 15% revenue increase in 1H25 and significant EBITDA improvement, accelerating towards profitability.
The Hydration Pharmaceuticals Company Limited (ASX:HPC) Reports FY2024 Financial Results
The Hydration Pharmaceuticals Company Limited (ASX:HPC) reports a 25.5% revenue decline in FY2024, asset divestiture, and a strategic focus on US growth.